Epilepsy Drugs Market, By Type of Epilepsy (Focal Epilepsy, Generalized Epilepsy, Reflex Epilepsy, and Others (Progressive Myoclonic Epilepsy, etc.)), By Drugs (1st Generation, 2nd Generation, and 3rd Generation), By Route of Administration (Oral, Injecta

Epilepsy Drugs Market, By Type of Epilepsy (Focal Epilepsy, Generalized Epilepsy, Reflex Epilepsy, and Others (Progressive Myoclonic Epilepsy, etc.)), By Drugs (1st Generation, 2nd Generation, and 3rd Generation), By Route of Administration (Oral, Injectable, and Others (Nasal, etc.)), By Age Group (Pediatric, Adults, and Geriatric), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Epilepsy is a chronic non-communicable disease characterized by recurrent seizures, which are brief episodes of involuntary movement that may involve a part of the body or the entire body. Its symptoms include abnormal electrical discharges in the brain causing seizures. It affects people of all ages but is more common in children and older adults. There is no cure for epilepsy but seizures can be controlled in about 70% of cases with medication. The global epilepsy drugs market is primarily driven by the increasing prevalence of epilepsy worldwide. Advancements in the treatment options with new drugs in the pipeline also support the growth of this market.

Market Dynamics

Global epilepsy drugs market growth is primarily driven by increasing prevalence of epilepsy worldwide. In 2022, it was estimated that over 50 million people have epilepsy globally according to the World Health Organization. The market also witnesses opportunities due to the rising healthcare expenditures across various countries. However, the market growth can be restrained by the expiry of patents of blockbuster drugs and price erosion faced by some generic drugs. The development of novel drugs for treatment-resistant epilepsy also presents growth opportunities in the market.

Key Features of the Study:

• This report provides in-depth analysis of the global epilepsy drugs market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global epilepsy drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Pfizer Inc., Sumitomo Pharma Co., Ltd., Novartis AG, Abbott, GSK plc., Teva Pharmaceutical Industries Ltd., Sanofi, Takeda Pharmaceutical Company Limited, Marinus Pharmaceuticals, Inc, Eisai Co., Ltd, DAIICHI SANKYO COMPANY, LIMITED, Mylan N.V., Dr. Reddy’s Laboratories Ltd, Sun Pharmaceutical Industries Ltd., Neurelis, Inc., and Supernus Pharmaceuticals, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global epilepsy drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global epilepsy drugs market

Market Segmentation

• Type of Epilepsy Insights
• Focal Epilepsy
• Generalized Epilepsy
• Reflex Epilepsy
• Others (Progressive Myoclonic Epilepsy, etc.)
• Drugs Insights
• 1st Generation
• 2nd Generation
• 3rd Generation
• Route of Administration Insights
• Oral
• Injectable
• Others (Nasal, etc.)
• Age Group Insights
• Pediatric
• Adults
• Geriatric
• Distribution Channel Insights
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Insights
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Pfizer Inc.
• Sumitomo Pharma Co., Ltd.
• Novartis AG
• Abbott
• GSK plc.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Takeda Pharmaceutical Company Limited
• Marinus Pharmaceuticals, Inc
• Eisai Co., Ltd
• DAIICHI SANKYO COMPANY, LIMITED
• Mylan N.V.
• Reddy’s Laboratories Ltd
• Sun Pharmaceutical Industries Ltd.
• Neurelis, Inc.
• Supernus Pharmaceuticals, Inc.